profit from every $100 of sales.
$0$100
Alterity Therapeutics
$1.96-6.67% today
-46.9% in 1 year
1-year low $1.961-year high $5.89
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Alterity Therapeutics sold, what it kept, and what it did with the cash.
Sales went from A$0 in 2022 to A$0 in 2025, with -A$12.1 million of profit last year.
SalesProfit
Alterity Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Alterity Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Alterity Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of AUD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -15 | -14 | -19 | -12 | |
| -15 | -14 | -19 | -12 | |
| -13 | -14 | -19 | -12 | |
| -3.18 | -3.42 | -3.12 | -1.14 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of AUD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 41 | 27 | 19 | 46 |
| Cash | 35 | 16 | 13 | 33 |
| Total debt | 0 | 0 | 0 | 0 |
| Total liabilities | 6 | 5 | 5 | 4 |
| 35 | 23 | 14 | 42 | |
| 4 | 4 | 6 | 11 | |
| -33.6% | -49.3% | -109.8% | -22.9% | |
| -36.2% | -60.5% | -138.6% | -28.6% |
Cash flow
| In millions of AUD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -12 | -20 | -13 | -11 | |
| 0 | 0 | 0 | – | |
| -12 | -20 | -13 | -11 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 2 | 1 | 1 | 1 |
Valuation
- –
- –
- –
- 1.7×
- 14.2×
- –
- –
- -14.8%
- -15.8%
- 0.0%
Profitability
- 96.8%
- -525.6%
- -380.7%
- -524.6%
- -31.3%
- -62.4%
- -30.2%
- -25.6%
- -37.1%
- 431.2%
Growth
- +5.8%
- –
- +9.2%
- –
- +39.3%
Financial health
- 2.4×
- 0.00
- 0.3%
- –
- 21.98
- 21.98
- 0.07
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 10%of 964
Bottom 33%of 911
Bottom 6%of 991
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Feb 25, 2026 | -0.38 | -0.23 | −65.9% |
| Aug 28, 2025 | -0.40 | -0.43 | +7.2% |
| Feb 28, 2025 | -0.00 | -0.53 | +99.9% |
| Feb 3, 2025 | -0.00 | – | – |
| Aug 29, 2024 | -0.00 | -0.05 | +96.2% |
| Apr 11, 2024 | -0.00 | – | – |
| Feb 28, 2024 | -0.00 | -0.11 | +97.5% |
| Jan 30, 2024 | -0.00 | – | – |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
36No pass
Benjamin Graham
59No pass
Philip Fisher
40No pass
Peter Lynch
40No pass
Joel Greenblatt
2No pass
Charlie Munger
39No pass
Terry Smith
41No pass
Questions about Alterity Therapeutics
Is Alterity Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Alterity Therapeutics AI analysis
What does Alterity Therapeutics do?
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. It is in Biotechnology.
Does Alterity Therapeutics pay a dividend?
No. Alterity Therapeutics does not pay a dividend at the moment.
Is Alterity Therapeutics stock halal?
No. Alterity Therapeutics does not pass our halal screen: its cash and confirmed interest-bearing investments are 60% of its market value, at or above the 33% limit. How we check
How has Alterity Therapeutics stock done over the past year?
Down 46.9% over the past twelve months, to $1.96. It traded between $1.96 and $5.89 and is 66.7% below its high.
Who are Alterity Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Alterity Therapeutics's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.